Evidence map›Paper›PMID 19359342›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2009

Molecular determinants of Grb14-mediated inhibition of insulin signaling.

Diana Goenaga, Cornelia Hampe, Nadège Carré, Katia Cailliau, Edith Browaeys-Poly, Dominique Perdereau, Lowenna J Holt, Roger J Daly, Jean Girard, Isabelle Broutin and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Diana GoenagaInstitut Cochin, Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8104, Paris, France.
Cornelia Hampe
Nadège Carré
Katia Cailliau
Edith Browaeys-Poly
Dominique Perdereau
Lowenna J Holt
Roger J Daly
Jean Girard
Isabelle Broutin
Tarik Issad
Anne-Françoise Burnol
Inserm · FRCentre National de la Recherche Scientifique · FRGarvan Institute of Medical Research · AUInstitut Cochin · FRLaboratoire de Cristallographie et RMN Biologiques · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Grb14 belongs to the Grb7 family of molecular adapters and was identified as an inhibitor of insulin signaling. Grb14 binds to activated insulin receptors (IR) and inhibits their catalytic activity. To gain more insight into the Grb14 molecular mechanism of action, we generated various mutants and studied the Grb14-IR interaction using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET) experiments. Biological activity was further analyzed using the Xenopus oocyte model and a functional complementation assay measuring cellular proliferation rate in Grb14 knockout mouse embryonic fibroblasts. These studies identified two important interaction sites, Grb14 L404-IR L1038 and Grb14 R385-IR K1168, involving the IR alphaC-helix and activation loop, respectively. Interestingly, the former involves residues that are likely to be crucial for the specificity of IR binding with regard to other members of the Grb7 family. In addition, mutation of the Grb14-S370 residue suggested that its phosphorylation status controlled the biological activity of the protein. We further demonstrated that insulin-induced Grb14-PDK1 interaction is required in addition to Grb14-IR binding to mediate maximal inhibition of insulin signaling. This study provides important insights into the molecular determinants of Grb14 action by demonstrating that Grb14 regulates insulin action at two levels, through IR binding and by interfering with downstream pathways. Indeed, a precise knowledge of the molecular mechanism of insulin signaling inhibition by Grb14 is a prerequisite for the development of insulin-sensitizing molecules to treat pathophysiological states such as obesity or type 2 diabetes.

Indexed as

Insulin AntagonistsAdaptor Proteins, Signal TransducingAmino Acid MotifsAnimalsCells, CulturedChlorocebus aethiopsCOS CellsHumansInsulinMiceMice, KnockoutProtein BindingProtein Serine-Threonine KinasesProtein Structure, TertiaryPyruvate Dehydrogenase Acetyl-Transferring KinaseReceptor, InsulinAdaptor Proteins, Signal TransducingGRB14 protein, humanInsulinInsulin AntagonistsPDK1 protein, humanPdk1 protein, mouseProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseReceptor, Insulin

Identifiers

PMID19359342
PMCPMC5419176
OpenAlexW2169839131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.